FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer By Ogkologos - February 13, 2025 37 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CodeBreaK 300 study Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... November 3, 2020 FDA Grants Accelerated Approval to Ponatinib with Chemotherapy for Newly Diagnosed... March 29, 2024 Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients... February 25, 2025 FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma February 12, 2021 Load more HOT NEWS Five-Year Outcomes with CAR T Cell Therapy This Saturday: National Prescription Drug Take-Back Day Thinking outside the box to tackle an aggressive children’s cancer Mental Health Awareness for Health Care Providers
